On January 12, 2022, the Centers for Medicare and Medicaid Services (“CMS”) issued a proposed new rule (the “Rule”) which, among other things, may fundamentally change controversial Direct and Indirect Remuneration (“DIR”) fees about... Read More
Blogs & Articles | Community, Retail Pharmacies | Digital Pharmacies | DIR Fees | Life Sciences | Pharmacy Law | Plan Sponsor PBM Contract Services

Independent pharmacies in Texas have significant protections from unfair practices by Pharmacy Benefit Managers (PBMs) in the form of HB 1919 and HB 1763. As previously discussed by Frier Levitt, HB 1763 provides Texas pharmacies with safeguards... Read More
Antitrust Tools Available to Combat PBM Abuse of Pharmacies | Blogs & Articles | DIR Fees | Life Sciences | Pharmacy Law | Plan Sponsor PBM Contract Services

Since going into effect on October 1, 2021, North Carolina Senate Bill 257 (SB 257) has provided independent pharmacies with significant protections against unfair PBM conduct and improved the landscape for pharmacies in North Carolina. The most... Read More
Antitrust Tools Available to Combat PBM Abuse of Pharmacies | Blogs & Articles | Community, Retail Pharmacies | Defending Pharmacies in PBM Audits | Life Sciences | Pharmacy Law

With the new year here, so come new challenges for independent pharmacies. But in addition to new challenges, there is also good reason for independent pharmacies to be optimistic about opportunities ahead and solutions to some of the challenges... Read More
Antitrust Tools Available to Combat PBM Abuse of Pharmacies | Defending Pharmacies in PBM Audits | Life Sciences | Pharmacy Law

On December 16, 2021, the Department of Health and Human Services, Office of Inspector General (“OIG”) issued a report analyzing nationwide trends in genetic tests for which payments were made under Medicare Part B. The OIG report follows a... Read More
Healthcare | Healthcare Law | Laboratories | Telehealth and Telemedicine | White Collar Defense and Government Investigation

New Jersey’s Acting Attorney General, Andrew J. Bruck, recently announced the largest enforcement action against fifteen companies across several industries for their unlawful hiring practices in violation of New Jersey’s Opportunity to Compete... Read More
Blogs & Articles | Employment Matters | Healthcare | Healthcare Law

In the patent infringement case Amarin v Hikma, the plaintiffs, a biopharmaceutical company, alleged induced patent infringement against both the generic manufacturer for its skinny label not carving out the patented indications sufficiently and the... Read More
COVID-19 Resources | Intellectual Property Services | Life Sciences | Pharmaceutical Manufacturers | Pharmacy Law